| abstract |
The present invention provides a method for treating HER 2 positive cancer or metastasis of HER 2 positive cancer in a patient, who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab or to successive monotherapies with trastuzumab and pertuzumab, comprising co-administering to said patient a therapeutically-effective amount of trastuzumab and pertuzumab simultaneously or sequentially. The invention also provides A kit which comprises trastuzumab and pertuzumab and a package insert instructing the user to co-administer trastuzumab and pertuzumab to a patient suffering from HER 2 positive cancer who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab. |